Affini-T CEO appears to have left startup, raising questions about company’s shutdownnews2025-09-17T12:18:28+00:00September 17th, 2025|Endpoints News|
Skyhawk reports positive first results in Huntington’s patients for oral drugnews2025-09-17T12:00:08+00:00September 17th, 2025|Endpoints News|
AstraZeneca’s Fasenra once again falls short in COPDnews2025-09-17T11:09:23+00:00September 17th, 2025|Endpoints News|
Roivant tees up dermatomyositis drug filing on heels of Phase 3 successnews2025-09-17T11:00:40+00:00September 17th, 2025|Endpoints News|
Ollin lands $100M to test eye drugs from Chinese partners and bring in more assetsnews2025-09-17T10:30:15+00:00September 17th, 2025|Endpoints News|
#EADV25: Sanofi claims Phase 2a success in chronic skin conditionnews2025-09-17T05:00:02+00:00September 17th, 2025|Endpoints News|
GSK budgets $30B to boost US presencenews2025-09-16T23:01:44+00:00September 16th, 2025|Endpoints News|
#EASD25: Lilly unwraps more Phase 3 obesity pill data, but they still lag behind Novo’s oral Wegovynews2025-09-16T22:01:48+00:00September 16th, 2025|Endpoints News|
Short-term government spending bill includes OTC drug user feesnews2025-09-16T20:01:26+00:00September 16th, 2025|Endpoints News|
Drugmakers submit plans to join 340B rebate model pilot programnews2025-09-16T19:52:48+00:00September 16th, 2025|Endpoints News|
